{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:29:18Z","timestamp":1782905358232,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00432-022-03920-7","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T19:03:36Z","timestamp":1642705416000},"page":"897-911","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The effect of intervention versus watchful waiting on disease progression and overall survival in smoldering multiple myeloma: a systematic review of randomized controlled trials"],"prefix":"10.1007","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8395-9361","authenticated-orcid":false,"given":"Ademola S.","family":"Ojo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somtochukwu G.","family":"Ojukwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Asemota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwasegun","family":"Akinyemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojisola O.","family":"Araoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Sarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"issue":"2","key":"3920_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF02698044","volume":"24","author":"A Avil\u00e9s","year":"2007","unstructured":"Avil\u00e9s A, Nambo MJ, Neri N, Casta\u00f1eda C, Cleto S, Huerta-Guzm\u00e1n J (2007) Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 24(2):227\u2013230. https:\/\/doi.org\/10.1007\/BF02698044","journal-title":"Med Oncol"},{"issue":"1","key":"3920_CR3","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.3747\/co.20.1055","volume":"20","author":"A Avil\u00e9s","year":"2013","unstructured":"Avil\u00e9s A, Neri N, Huerta-Guzm\u00e1n J, Nambo MJ (2013) Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation. Curr Oncol 20(1):e13-20. https:\/\/doi.org\/10.3747\/co.20.1055","journal-title":"Curr Oncol"},{"key":"3920_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF02698044","volume":"24","author":"A Aviles","year":"2007","unstructured":"Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S, Huerta-Guzman J (2007) Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 24:227\u2013230","journal-title":"Med Oncol"},{"issue":"13","key":"3920_CR5","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1158\/1078-0432.CCR-18-3470","volume":"25","author":"TA Brighton","year":"2019","unstructured":"Brighton TA, Khot A, Harrison SJ, Ghez D, Weiss BM, Kirsch A, Magen H, Gironella M, Oriol A, Streetly M, Kranenburg B, Qin X, Bandekar R, Hu P, Guilfoyle M, Qi M, Nemat S, Goldschmidt H (2019) Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma. Clin Cancer Res 25(13):3772\u20133775. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3470","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"3920_CR6","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1182\/blood-2018-99-117871","volume":"132","author":"M Bustoros","year":"2018","unstructured":"Bustoros M, Liu CJ, Reyes K et al (2018) Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma. Blood 132(suppl 1):804","journal-title":"Blood"},{"issue":"1","key":"3920_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/jbmr.3877","volume":"35","author":"RB Conley","year":"2020","unstructured":"Conley RB, Adib G, Adler RA, \u00c5kesson KE, Alexander IM, Amenta KC, Blank RD, Brox WT, Carmody EE, Chapman-Novakofski K, Clarke BL, Cody KM, Cooper C, Crandall CJ, Dirschl DR, Eagen TJ, Elderkin AL, Fujita M, Greenspan SL, Halbout P, Hochberg MC, Javaid M, Jeray KJ, Kearns AE, King T, Koinis TF, Koontz JS, Ku\u017ema M, Lindsey C, Lorentzon M, Lyritis GP, Michaud LB, Miciano A, Morin SN, Mujahid N, Napoli N, Olenginski TP, Puzas JE, Rizou S, Rosen CJ, Saag K, Thompson E, Tosi LL, Tracer H, Khosla S, Kiel DP (2020) Secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition. J Bone Miner Res 35(1):36\u201352. https:\/\/doi.org\/10.1002\/jbmr.3877","journal-title":"J Bone Miner Res"},{"key":"3920_CR8","doi-asserted-by":"publisher","unstructured":"D'Arena G, Gobbi PG, Broglia C, Sacchi S, Quarta G, Baldini L, Iannitto E, Falcone A, Guariglia R, Pietrantuono G, Villani O, Martorelli MC, Mansueto G, Sanpaolo G, Cascavilla N, Musto P; Gimema (Gruppo Italiano Malattie Ematologiche Dell'Adulto); Multiple Myeloma Working Party; Gisl (Gruppo Italiano Studio Linfomi) Cooperative Group (2011) Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leuk Lymphoma. 52(5):771\u2013775 https:\/\/doi.org\/10.3109\/10428194.2011.553000","DOI":"10.3109\/10428194.2011.553000"},{"issue":"6","key":"3920_CR9","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3324\/haematol.2014.120121","volume":"100","author":"M Delforge","year":"2015","unstructured":"Delforge M, Minuk L, Eisenmann JC, Arnulf B, Canepa L, Fragasso A, Leyvraz S, Langer C, Ezaydi Y, Vogl DT, Giraldo-Castellano P, Yoon SS, Zarnitsky C, Escoffre-Barbe M, Lemieux B, Song K, Bahlis NJ, Guo S, Monzini MS, Ervin-Haynes A, Houck V, Facon T (2015) Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica 100(6):826\u2013833. https:\/\/doi.org\/10.3324\/haematol.2014.120121","journal-title":"Haematologica"},{"issue":"2","key":"3920_CR10","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","volume":"111","author":"A Dispenzieri","year":"2008","unstructured":"Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, Clark RJ, Melton LJ 3rd, Gertz MA, Kumar SK, Fonseca R, Jelinek DF, Rajkumar SV (2008) Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111(2):785\u2013789. https:\/\/doi.org\/10.1182\/blood-2007-08-108357","journal-title":"Blood"},{"key":"3920_CR11","doi-asserted-by":"publisher","unstructured":"Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36(3):842\u201354. https:\/\/doi.org\/10.1002\/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u","DOI":"10.1002\/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u"},{"issue":"7","key":"3920_CR12","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1586\/14737140.7.7.945","volume":"7","author":"P Falco","year":"2007","unstructured":"Falco P, Bringhen S, Avonto I, Gay F, Morabito F, Boccadoro M, Palumbo A (2007) Melphalan and its role in the management of patients with multiple myeloma. Expert Rev Anticancer Ther 7(7):945\u2013957. https:\/\/doi.org\/10.1586\/14737140.7.7.945","journal-title":"Expert Rev Anticancer Ther"},{"key":"3920_CR13","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Sanz R, Oriol A, Moreno MJ, de la Rubia J, Payer AR, Hern\u00e1ndez MT, Palomera L, Teruel AI, Blanchard MJ, Gironella M, Ribas P, Bargay J, Abell\u00e1 E, Granell M, Ocio EM, Ribera JM, San Miguel JF, Mateos MV; Spanish Myeloma Group (GEM\/PETHEMA) (2015) Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. Haematologica. 100(9):1207\u201313. https:\/\/doi.org\/10.3324\/haematol.2015.128439","DOI":"10.3324\/haematol.2015.128439"},{"key":"3920_CR14","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1182\/blood.V128.22.976.976","volume":"128","author":"IM Ghobrial","year":"2016","unstructured":"Ghobrial IM, Badros AZ, Vredenburgh JJ et al (2016) Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma. Blood 128:976","journal-title":"Blood"},{"key":"3920_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004023","author":"Y He","year":"2003","unstructured":"He Y, Wheatley K, Clark O, Glasmacher A, Ross H, Djulbegovic B (2003) Early versus deferred treatment for early stage multiple myeloma. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD004023","journal-title":"Cochrane Database Syst Rev"},{"key":"3920_CR16","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org\/handbook"},{"issue":"2","key":"3920_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","volume":"50","author":"M Hjorth","year":"1993","unstructured":"Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rodjer S, Westin J (1993) Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - A randomized study. Eur J Haematol 50(2):95\u2013102","journal-title":"Eur J Haematol"},{"issue":"suppl 1","key":"3920_CR18","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1182\/blood.V130.Suppl_1.510.510","volume":"130","author":"C Hofmeister","year":"2017","unstructured":"Hofmeister C, Chari A, Cohen Y et al (2017) Daratumumab monotherapy for patients with intermediate or high-risk smoldering multiple myeloma (SMM): Centaurus, a randomized, open-label, multicenter phase 2 study. Blood 130(suppl 1):510. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.510.510","journal-title":"Blood"},{"key":"3920_CR20","unstructured":"https:\/\/www.cancer.org\/cancer\/multiple-myeloma\/about\/key-statistics.html. Accessed on October 29, 2021"},{"key":"3920_CR1","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03289299"},{"key":"3920_CR19","unstructured":"https:\/\/ash.confex.com\/ash\/2021\/webprogram\/Paper148423.html"},{"issue":"5","key":"3920_CR21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"International Myeloma Working Group","year":"2003","unstructured":"International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group. Br J Haematol 121(5):749\u2013757","journal-title":"Br J Haematol"},{"key":"3920_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_278915","volume":"40","author":"NS Joseph","year":"2020","unstructured":"Joseph NS, Dhodapkar MV, Lonial S (2020) The role of early intervention in high-risk smoldering myeloma. Am Soc Clin Oncol Educ Book 40:1\u20139. https:\/\/doi.org\/10.1200\/EDBK_278915","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2\u20133","key":"3920_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/10376178.2019.1623699","volume":"55","author":"HY Kang","year":"2019","unstructured":"Kang HY, Choi EY (2019) Factors influencing quality of life in patients with multiple myeloma. Contemp Nurse 55(2\u20133):109\u2013121. https:\/\/doi.org\/10.1080\/10376178.2019.1623699","journal-title":"Contemp Nurse"},{"issue":"2","key":"3920_CR24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1200\/JCO.18.01398","volume":"37","author":"SK Kumar","year":"2019","unstructured":"Kumar SK, Gertz MA, Dispenzieri A (2019) Validation of mayo clinic staging system for light chain amyloidosis with high-sensitivity troponin. J Clin Oncol 37(2):171\u2013173. https:\/\/doi.org\/10.1200\/JCO.18.01398","journal-title":"J Clin Oncol"},{"issue":"24","key":"3920_CR25","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","volume":"302","author":"RA Kyle","year":"1980","unstructured":"Kyle RA, Greipp PR (1980) Smoldering multiple myeloma. N Engl J Med 302(24):1347\u20131349. https:\/\/doi.org\/10.1056\/NEJM198006123022405","journal-title":"N Engl J Med"},{"issue":"25","key":"3920_CR26","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, Melton LJ 3rd, Rajkumar SV (2007) Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 356(25):2582\u20132590. https:\/\/doi.org\/10.1056\/NEJMoa070389","journal-title":"N Engl J Med"},{"issue":"6","key":"3920_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK (2018) Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J 8(6):59. https:\/\/doi.org\/10.1038\/s41408-018-0077-4","journal-title":"Blood Cancer J"},{"issue":"1","key":"3920_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/2162-3619-1-27","volume":"1","author":"T Latif","year":"2012","unstructured":"Latif T, Chauhan N, Khan R, Moran A, Usmani SZ (2012) Thalidomide and its analogues in the treatment of multiple myeloma. Exp Hematol Oncol 1(1):27. https:\/\/doi.org\/10.1186\/2162-3619-1-27","journal-title":"Exp Hematol Oncol"},{"issue":"suppl 1","key":"3920_CR29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1182\/blood-2018-154","volume":"132","author":"CJ Liu","year":"2018","unstructured":"Liu CJ, Ghobrial IM, Bustoros M et al (2018) Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma. Blood 132(suppl 1):154","journal-title":"Blood"},{"issue":"11","key":"3920_CR30","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1200\/JCO.19.01740","volume":"38","author":"S Lonial","year":"2020","unstructured":"Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O\u2019Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV (2020) Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol 38(11):1126\u20131137. https:\/\/doi.org\/10.1200\/JCO.19.01740","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"3920_CR31","doi-asserted-by":"publisher","first-page":"8118","DOI":"10.1182\/blood-2019-123205","volume":"184","author":"E Manasanch","year":"2019","unstructured":"Manasanch E, Jagannath S (2019) A multicenter phase II single arm trial of isatuximab in patients with high risk smoldering multiple myeloma (HRSMM). Blood 184(suppl 1):8118. https:\/\/doi.org\/10.1182\/blood-2019-123205","journal-title":"Blood"},{"issue":"1","key":"3920_CR32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1046\/j.1365-2141.2002.03549.x","volume":"118","author":"A Mart\u00edn","year":"2002","unstructured":"Mart\u00edn A, Garc\u00eda-Sanz R, Hern\u00e1ndez J, Blad\u00e9 J, Suqu\u00eda B, Fern\u00e1ndez-Calvo J, Gonz\u00e1lez M, Mateo G, Orfao A, San Miguel JF (2002) Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. Br J Haematol 118(1):239\u2013242. https:\/\/doi.org\/10.1046\/j.1365-2141.2002.03549.x","journal-title":"Br J Haematol"},{"issue":"8","key":"3920_CR33","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","volume":"17","author":"MV Mateos","year":"2016","unstructured":"Mateos MV, Hern\u00e1ndez MT, Giraldo P, de la Rubia J, de Arriba F, Corral LL, Rosi\u00f1ol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, L\u00f3pez J, Argui\u00f1ano JM, Quintana N, Garc\u00eda JL, Blad\u00e9 J, Lahuerta JJ, Miguel JS (2016) Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol 17(8):1127\u20131136. https:\/\/doi.org\/10.1016\/S1470-2045(16)30124-3","journal-title":"Lancet Oncol"},{"issue":"10","key":"3920_CR34","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","volume":"10","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Kumar S, Dimopoulos MA, Gonz\u00e1lez-Calle V, Kastritis E, Hajek R, De Larrea CF, Morgan GJ, Merlini G, Goldschmidt H, Geraldes C, Gozzetti A, Kyriakou C, Garderet L, Hansson M, Zamagni E, Fantl D, Leleu X, Kim BS, Esteves G, Ludwig H, Usmani S, Min CK, Qi M, Ukropec J, Weiss BM, Rajkumar SV, Durie BGM, San-Miguel J (2020) international myeloma working group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J 10(10):102. https:\/\/doi.org\/10.1038\/s41408-020-00366-3","journal-title":"Blood Cancer J"},{"key":"3920_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003188.pub4","author":"R Mhaskar","year":"2017","unstructured":"Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B (2017) Bisphosphonates in multiple myeloma: an updated network meta-analysis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD003188.pub4","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"3920_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","volume":"18","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni L, Kochenderfer JN (2021) CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol 18(2):71\u201384. https:\/\/doi.org\/10.1038\/s41571-020-0427-6","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"3920_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA (2015) PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4(1):1. https:\/\/doi.org\/10.1186\/2046-4053-4-1","journal-title":"Syst Rev"},{"issue":"9","key":"3920_CR38","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.3109\/10428190309178778","volume":"44","author":"P Musto","year":"2003","unstructured":"Musto P, Falcone A, Sanpaolo G, Bodenizza C, Cascavilla N, Melillo L, Scalzulli PR, Dell\u2019Olio M, La Sala A, Mantuano S, Nobile M, Carella AM (2003) Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. Leuk Lymphoma 44(9):1545\u20131548. https:\/\/doi.org\/10.3109\/10428190309178778","journal-title":"Leuk Lymphoma"},{"key":"3920_CR39","doi-asserted-by":"publisher","unstructured":"Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V, Andriani A, D'Arena G, Balleari E, Pietrantuono G, Boccadoro M, Palumbo A; GIMEMA (Italian Group for Adult Hematologic Diseases)\/Multiple Myeloma Working Party and the Italian Myeloma Network. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer. 2008;113(7):1588\u201395. https:\/\/doi.org\/10.1002\/cncr.23783. Erratum in: Cancer. 2008;113(10):2835.","DOI":"10.1002\/cncr.23783"},{"key":"3920_CR40","doi-asserted-by":"publisher","unstructured":"Nsiala L, Bobin A, Levy A, Gruchet C, Sabirou F, Gardeney H, Cailly L, Manier S, Moya N, Tomowiak C, Guidez S, Leleu X, Decaux O. Smoldering multiple myeloma: biology, clinical manifestations and management. Leuk Lymphoma. 2021 https:\/\/doi.org\/10.1080\/10428194.2021.1992615","DOI":"10.1080\/10428194.2021.1992615"},{"issue":"1","key":"3920_CR41","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ajh.23868","volume":"90","author":"RZ Orlowski","year":"2015","unstructured":"Orlowski RZ, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T, Goranova-Marinova V, Dimopoulos MA, Cavenagh JD, \u0160pi\u010dka I, Maiolino A, Suvorov A, Blad\u00e9 J, Samoylova O, Puchalski TA, Reddy M, Bandekar R, van de Velde H, Xie H, Rossi JF (2015) A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol 90(1):42\u201349. https:\/\/doi.org\/10.1002\/ajh.23868","journal-title":"Am J Hematol"},{"issue":"7","key":"3920_CR42","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","volume":"110","author":"E P\u00e9rez-Persona","year":"2007","unstructured":"P\u00e9rez-Persona E, Vidriales MB, Mateo G, Garc\u00eda-Sanz R, Mateos MV, de Coca AG, Galende J, Mart\u00edn-Nu\u00f1ez G, Alonso JM, de Las HN, Hern\u00e1ndez JM, Mart\u00edn A, L\u00f3pez-Berges C, Orfao A, San Miguel JF (2007) New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 110(7):2586\u20132592. https:\/\/doi.org\/10.1182\/blood-2007-05-088443","journal-title":"Blood"},{"issue":"5","key":"3920_CR43","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1634\/theoncologist.2010-0225","volume":"16","author":"S Pozzi","year":"2011","unstructured":"Pozzi S, Raje N (2011) The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. Oncologist 16(5):651\u2013662. https:\/\/doi.org\/10.1634\/theoncologist.2010-0225","journal-title":"Oncologist"},{"issue":"5","key":"3920_CR44","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791.Erratum.In:AmJHematol.2020;95(11):1444","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV (2020) Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 95(5):548\u2013567. https:\/\/doi.org\/10.1002\/ajh.25791.Erratum.In:AmJHematol.2020;95(11):1444","journal-title":"Am J Hematol"},{"issue":"12","key":"3920_CR45","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538\u2013e548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"issue":"20","key":"3920_CR46","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","volume":"125","author":"SV Rajkumar","year":"2015","unstructured":"Rajkumar SV, Landgren O, Mateos MV (2015) Smoldering multiple myeloma. Blood 125(20):3069\u20133075. https:\/\/doi.org\/10.1182\/blood-2014-09-568899","journal-title":"Blood"},{"issue":"6","key":"3920_CR47","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/bjc.1994.474","volume":"70","author":"A Riccardi","year":"1994","unstructured":"Riccardi A, Ucci G, Luoni R et al (1994) Treatment of multiple myeloma according to the extension of the disease: a prospective, randomized study comparing a less with a more aggressive cystostatic policy. Cooperative group of study and treatment of multiple myeloma. Br J Cancer 70(6):1203\u20131210. https:\/\/doi.org\/10.1038\/bjc.1994.474","journal-title":"Br J Cancer"},{"issue":"7","key":"3920_CR48","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","volume":"82","author":"A Riccardi","year":"2000","unstructured":"Riccardi A, Mora O, Tinelli C et al (2000) Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative group of study and treatment of multiple myeloma. Br J Cancer 82(7):1254\u20131260. https:\/\/doi.org\/10.1054\/bjoc.1999.1087","journal-title":"Br J Cancer"},{"key":"3920_CR49","doi-asserted-by":"publisher","first-page":"15s","DOI":"10.1200\/JCO.2019.37.15_suppl.8000","volume":"37","author":"J San Miguel","year":"2019","unstructured":"San Miguel J, Mateos MV, Gonzalez V et al (2019) Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. J Clin Oncol 37:15s. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.8000","journal-title":"J Clin Oncol"},{"issue":"26","key":"3920_CR50","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1182\/blood-2013-12-546374.Erratum.In:Blood.2014;124(7):1201","volume":"123","author":"J San-Miguel","year":"2014","unstructured":"San-Miguel J, Blad\u00e9 J, Shpilberg O, Grosicki S, Maloisel F, Min CK, Polo Zarzuela M, Robak T, Prasad SV, Tee Goh Y, Laubach J, Spencer A, Mateos MV, Palumbo A, Puchalski T, Reddy M, Uhlar C, Qin X, van de Velde H, Xie H, Orlowski RZ (2014) Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 123(26):4136\u20134142. https:\/\/doi.org\/10.1182\/blood-2013-12-546374.Erratum.In:Blood.2014;124(7):1201","journal-title":"Blood"},{"issue":"11","key":"3920_CR51","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1182\/blood-2014-12-613927","volume":"126","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Jacobus S, Fonseca R, Weiss M, Callander NS, Chanan-Khan AA, Rajkumar SV (2015) Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood 126(11):1294\u20131301. https:\/\/doi.org\/10.1182\/blood-2014-12-613927","journal-title":"Blood"},{"issue":"2","key":"3920_CR52","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/leu.2013.199","volume":"28","author":"BA Walker","year":"2014","unstructured":"Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, Mirabella F, Lopez-Corral L, Humphray S, Murray L, Ross M, Bentley D, Guti\u00e9rrez NC, Garcia-Sanz R, San Miguel J, Davies FE, Gonzalez D, Morgan GJ (2014) Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 28(2):384\u2013390. https:\/\/doi.org\/10.1038\/leu.2013.199","journal-title":"Leukemia"},{"issue":"1","key":"3920_CR53","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/leu.2012.236","volume":"27","author":"TE Witzig","year":"2013","unstructured":"Witzig TE, Laumann KM, Lacy MQ, Hayman SR, Dispenzieri A, Kumar S, Reeder CB, Roy V, Lust JA, Gertz MA, Greipp PR, Hassoun H, Mandrekar SJ, Rajkumar SV (2013) A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia 27(1):220\u2013225. https:\/\/doi.org\/10.1038\/leu.2012.236","journal-title":"Leukemia"},{"issue":"5","key":"3920_CR54","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1182\/blood.v99.5.1745","volume":"99","author":"F Zhan","year":"2002","unstructured":"Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J Jr (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99(5):1745\u20131757. https:\/\/doi.org\/10.1182\/blood.v99.5.1745","journal-title":"Blood"},{"issue":"7","key":"3920_CR55","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/leu.2014.59","volume":"28","author":"S Zhao","year":"2014","unstructured":"Zhao S, Choi M, Heuck C, Mane S, Barlogie B, Lifton RP, Dhodapkar MV (2014) Serial exome analysis of disease progression in premalignant gammopathies. Leukemia 28(7):1548\u20131552. https:\/\/doi.org\/10.1038\/leu.2014.59","journal-title":"Leukemia"},{"key":"3920_CR56","doi-asserted-by":"publisher","first-page":"5599","DOI":"10.2147\/CMAR.S205623","volume":"11","author":"AL Zhao","year":"2019","unstructured":"Zhao AL, Shen KN, Wang JN, Huo LQ, Li J, Cao XX (2019) Early or deferred treatment of smoldering multiple myeloma: a meta-analysis on randomized controlled studies. Cancer Manag Res 11:5599\u20135611. https:\/\/doi.org\/10.2147\/CMAR.S205623","journal-title":"Cancer Manag Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-03920-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-03920-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-03920-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T02:08:19Z","timestamp":1647569299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-03920-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["3920"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-03920-7","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,20]]},"assertion":[{"value":"22 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}